Metabolon, Inc., a leader in metabolomics solutions, has partnered with the China Kadoorie Biobank (CKB) to conduct a significant study on plasma metabolomics biomarkers. Announced on September 9, 2025, this collaboration aims to explore the intricate relationships between lifestyle, environmental, genetic, and socioeconomic factors in the development of common diseases.
Located in Morrisville, North Carolina, Metabolon will utilize its Global Discovery Panel™ to profile biomarkers from CKB, one of the largest cohort studies globally. Established between 2004 and 2008 by the University of Oxford and various Chinese institutions, including Peking University, CKB seeks to address the historical focus of clinical trials on predominantly white European populations. This partnership reflects a growing recognition of the need to include more diverse ethnic groups in health research.
The study will involve analyzing an initial set of 4,000 samples, linking them with other multiomics data such as genotyping and proteomics. According to Kari Wong, Scientific Strategy Director at Metabolon, “Metabolomics offers a comprehensive representation of the phenotype and enhances multiomics research by linking gene expression to physiology.” This connection is essential for accurately identifying molecular entities and understanding key biochemical pathways associated with health and disease.
The collaboration is expected to generate robust evidence that will inform future research on the influence of various factors on health outcomes. Zhengming Chen, Richard Peto Professor of Epidemiology at Oxford Population Health, expressed enthusiasm for the potential discoveries, stating, “The study will provide critical evidence to inform future scaling up of metabolomics assays in CKB and other large cohort studies in diverse populations.”
This partnership demonstrates Metabolon’s commitment to advancing multiomics research and its capability to profile large, diverse cohorts. The insights gained from this study could lead to more tailored approaches to disease prevention and treatment, ultimately enhancing global health outcomes.
For further information, Metabolon provides a detailed overview of its Global Discovery Panel and multiomics solutions on its website. With over 20 years of experience, the company has conducted more than 15,000 projects and published over 3,500 research articles, establishing itself as a trusted leader in the field.
Metabolomics itself is a crucial aspect of biomedical research, offering insights into the functional state of biological systems. By examining the small molecules present in biological samples, researchers can gain a deeper understanding of how genetic and environmental factors interact to influence health.
This partnership between Metabolon and CKB not only enhances the scientific community’s understanding of health and disease but also emphasizes the importance of inclusivity in medical research.
